Literature DB >> 17851442

4'-Acetamidochalcone derivatives as potential antinociceptive agents.

Fátima de Campos-Buzzi1, Pâmela Padaratz, Aleandra Vergilina Meira, Rogério Corrêa, Ricardo José Nunes, Valdir Cechinel-Filho.   

Abstract

Nine acetamidochalcones were synthesized and evaluated as antinociceptive agents using the mice writhing test. Given intraperitoneally all the compounds were more effective than the two reference analgesic drugs (acetylsalicylic acid and acetaminophen) used for comparison. N-{4-[(2E)-3-(4-nitrophenyl)prop-2-enoyl]phenyl}acetamide (6) was the most effective compound and was therefore selected for more detailed studies. It caused dose-related inhibition in the writhing test, being about 32 to 34-fold more potent than the standard drugs. It was also effective in the second phase of the formalin test and the capsaicin test. These acetamidochalcones, especially compound 6, might be further used as models to obtain new and more potent analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851442      PMCID: PMC6149446          DOI: 10.3390/12040896

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  18 in total

Review 1.  A review of anti-infective and anti-inflammatory chalcones.

Authors:  Zdzisława Nowakowska
Journal:  Eur J Med Chem       Date:  2006-11-15       Impact factor: 6.514

2.  The abdominal constriction response and its suppression by analgesic drugs in the mouse.

Authors:  H O Collier; L C Dinneen; C A Johnson; C Schneider
Journal:  Br J Pharmacol Chemother       Date:  1968-02

3.  Effects of the nitro-group on the mutagenicity and toxicity of some benzamines.

Authors:  K T Chung; C A Murdock; Y Zhou; S E Stevens; Y S Li; C I Wei; S Y Fernando; M W Chou
Journal:  Environ Mol Mutagen       Date:  1996       Impact factor: 3.216

4.  Modified formalin test: characteristic biphasic pain response.

Authors:  Manabu Shibata; Tsuyako Ohkubo; Hiroshi Takahashi; Reizo Inoki
Journal:  Pain       Date:  1989-09       Impact factor: 6.961

5.  A new potential cyclooxygenase-2 inhibitor, pyridinic analogue of nimesulide.

Authors:  Catherine Michaux; Caroline Charlier; Fabien Julémont; Xavier de Leval; Jean-Michel Dogné; Bernard Pirotte; François Durant
Journal:  Eur J Med Chem       Date:  2005-10-11       Impact factor: 6.514

6.  Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood.

Authors:  Syahida Ahmad; Daud A Israf; Nordin Hj Lajis; Khozirah Shaari; Habsah Mohamed; Afiza A Wahab; Khaizurin T Ariffin; Wei Yee Hoo; Nasaruddin A Aziz; Arifah A Kadir; Mohamad R Sulaiman; Muhammad N Somchit
Journal:  Eur J Pharmacol       Date:  2006-04-05       Impact factor: 4.432

7.  The formalin test in mice: dissociation between inflammatory and non-inflammatory pain.

Authors:  Steinar Hunskaar; Kjell Hole
Journal:  Pain       Date:  1987-07       Impact factor: 6.961

8.  Studies on new cyclic imides obtained from aminophenazone with analgesic properties. Potent effects of a 3,4-dichloromaleimide derivative.

Authors:  Fátima de Campos; Rogério Corrêa; Márcia Maria de Souza; Rosendo Augusto Yunes; Ricardo José Nunes; Valdir Cechinel-Filho
Journal:  Arzneimittelforschung       Date:  2002

Review 9.  Mutagenicity and genotoxicity of nitroarenes. All nitro-containing chemicals were not created equal.

Authors:  H S Rosenkranz; R Mermelstein
Journal:  Mutat Res       Date:  1983-04       Impact factor: 2.433

10.  Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines.

Authors:  M Satyanarayana; Priti Tiwari; Brajendra K Tripathi; A K Srivastava; Ram Pratap
Journal:  Bioorg Med Chem       Date:  2004-03-01       Impact factor: 3.641

View more
  1 in total

1.  Activity-Guided Isolation of Bioactive Constituents with Antinociceptive Activity from Muntingia calabura L. Leaves Using the Formalin Test.

Authors:  Mohd Izwan Mohamad Yusof; Mohd Zaki Salleh; Teh Lay Kek; Norizan Ahmat; Nik Fatini Nik Azmin; Zainul Amiruddin Zakaria
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-21       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.